08:00 Thu 26 Sep 2019
Scancell Hlds - Posters at Cancer Immunotherapy Conference
("Scancell" or the "Company")
Scancell to present six posters at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Scancell, the developer of novel immunotherapies for the treatment of cancer, will be presenting at the 5th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, being held at the Espace
The 2019 meeting hosted by the
Starting today, Professor
The additional poster presentations contribute to the continued scientific understanding of Scancell's cancer immunotherapy platform, Moditope®, targeting stress induced post translational modifications (siPTMs). These data are important validators as Scancell advances the lead Moditope programme, Modi-1, towards the clinic and also to the continued preclinical advancement of Modi-2.
The poster presentations are as follows:
· "An ultraspecific monoclonal antibody (FG2811) recognises a novel marker on stem memory T cells and induces cell proliferation and differentiation in vitro and in vivo" by Scancell,
· "Post-translationally modified antigens are good targets for cancer immunotherapy but some patients have antigen specific T-regs that may need to be neutralized" by
· "Improving selection criteria for post translationally modified CD4 epitopes using computer algorithms" by
· "Carbamylation of lysine residues mediated by MDSCs in the tumour environment make excellent targets for CD4 T cell mediated cancer immunotherapy" by Scancell,
· "Targeting citrullinated vimentin and enolase with cytotoxic CD4 T cells relies upon MHC-II expression by tumors, reduces myeloid suppressor cells and directly kills tumor cells" by Scancell,
· "Citrullinated glucose-regulated protein 78 is a candidate target for cancer immunotherapy" by
All posters will be made available on the Company's website, at https://www.scancell.co.uk/scientific-papers-posters
For Further Information:
| | |
Dr | | +44 (0) 20 3727 1000 |
Dr | | |
| | |
(Nominated Adviser and Corporate broker) | | |
| | +44 (0) 20 7886 2500 |
| | |
FTI Consulting | | +44 (0) 20 3727 1000 |
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody®, Moditope® and AvidiMab™ technology platforms.
ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.
· SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.
· SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with
Moditope® represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM). It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope® alone, or in combination with other agents, has the potential to treat a wide variety of cancers.
· Modi-1 is being developed for the treatment of solid tumours including triple negative breast cancer, ovarian cancer and head and neck cancer.
AvidiMab™ is a patent protected technology platform which increases the avidity of human antibodies by promoting non-covalent Fc-Fc interactions. This modification induces the direct tumour cell killing properties of Scancell's anti-glycan monoclonal antibodies (mAbs) but has broad potential to increase the avidity or potency of any therapeutic monoclonal antibody including those being developed for autoimmune diseases, as well as cancer.
For further details, please see our website: www.scancell.co.uk
This information is provided by RNS, the news service of the
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
